Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Liver Cancer

Inclusion Criteria:

* 18-75 years old
* The patient is diagnosed as advanced liver cancer,MUC1 is positive
* There is at least one tumor should be measured,and length≥10mm of focus not at lymph node or length≥10mm of focus at lymph node
* C interval of BCLC
* The patient can't tolerate system(systemic chemotherapy/molecular targeted therapy) or local therapies
* Child-Pugh Score ≤7
* If the patient received adjuvant chemotherapy after local treatment,the time should be more than 4 weeks after the end of chemotherapy, and disease progression or metastasis patients can also assigned into the group
* The time of surgical treatment≥ 3 months ;At the end of the intervention,radiotherapy and the end of the ablation time is more than 4 weeks
* The expected survival time ≥12 weeks
* The patient did not took any antitumor drugs within 4 weeks(any antitumor drugs, Chinese patent medicine including Delisheng injection,Kanglaite injection, Aidi injection
* Hepatitis B virus(HBV) DNA\<10\^4copies/ml（2000IU/ml)
* Serum albumin≥28g/L,TBIL≤1.5×ULN,electrolyte is normal, proteinuria = 0 \~ 1 +, serum creatinine≤1.5 x ULN
* Tests of blood,liver and kidney should meet the following criteria:WBC≥3×10\^9/L,NEUT≥1×10\^9/L,Hemoglobin ≥90 g/L,ANC≥1.5×109/L,PLT≥75×10\^9/L
* No serious disease are conflicts with the solution(such as autoimmune disease,immunodeficiency,organ transplantation)
* Sign the informed consent

Exclusion Criteria:

* Severe cirrhosis, medium or above ascites
* Cancer embolus in the main portal vein and first branch, Hepatic duct and first branch, hepatic vein, inferior vena cava
* Patient of second primary tumor or multiple primary cancer
* Patients of T cell lymphoma、myeloma,and patients are using immunosuppressant
* Systemic autoimmune diseases, allergic constitution or immunocompromised patients
* Patients of chronic diseases need immune stimulant or hormone therapy
* Patients of active bleeding or coagulant function abnormality（PT\>16s、APTT\>43s、TT\>21s、INR≥2）,and patients of bleeding tendency or are receiving thrombolysis and anticoagulation and antiplatelet therapy
* Women who is pregnant or during breast feeding or plan to pregnant in 2 years,and not willing to contraception during the test
* Patients with brain、dura mater metastases or history of psychogenic
* Gastrointestinal bleeding in the past six months or have clear gastrointestinal bleeding tendency,such as: patients of local active ulcerative lesions, defecate occult blood + + above shall not enter into group; defecate occult blood + depend on gastroscopy
* Patients with severe stomach/esophageal varices and need for intervention treatment
* Patients with abdominal fistula, gastrointestinal perforation or abdominal abscess within 4 weeks before the first treatment
* Patients with glomerular filtration rate abnormal obviously(The endogenous creatinine clearance \< 60 ml/min or serum creatinine \> 1.5 x ULN)
* Positive for HIV antibody
* Patients who are allergic to computed tomography (CT) and magnetic resonance imaging (MRI) contrast agents at the same time, can't imaging assay
* Patients accepted any experimental drugs or pilot medical apparatus and instruments in the past 4 weeks of first treatment
* Other reasons the researchers think not suitable